The US Food and Drug Administration (FDA) has declined to approve linvoseltamab (Regeneron), a bispecific antibody being evaluated to treat relapsed/refractory multiple myeloma after progression on at least three previous therapies. Tuesday evening, Regeneron announced that it had received a complete response letter from the FDA regarding its Biologics License Application for linvoseltamab…
